Active, not recruitingPhase 3NCT02544308

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Studying Plasmacytoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University College, London
Principal Investigator
Roger Owen, Rph
St James's University Hospital
Intervention
Lenalidomide(drug)
Enrollment
36 target
Eligibility
18 years · All sexes
Timeline
2017 – 2026

Study locations (13)

Collaborators

Cancer Research UK · Celgene

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02544308 on ClinicalTrials.gov

Other trials for Plasmacytoma

Additional recruiting or active studies for the same condition.

See all trials for Plasmacytoma →

← Back to all trials